Search papers, labs, and topics across Lattice.
This paper introduces ATLAS, a coupled graph-policy distillation framework designed to enhance medication safety for older adults with multimorbidity by structuring guideline evidence into a medication-safety graph. By employing a patient-specific medication conflict graph (PMCG) and a risk-first multi-agent policy, ATLAS effectively screens for contraindications and identifies safer medication alternatives based on patient-specific data. The framework outperforms existing systems, achieving significant improvements in decision-making performance and safety reasoning across multiple benchmarks, including a 53.73-point increase in Strict Success Rate compared to the strongest proprietary LLM baseline.
ATLAS outperforms existing systems in medication safety for older adults, achieving a 53.73-point lead in decision-making accuracy over top proprietary models.
Large language model (LLM) agents can support medication review between clinical visits, but safe choices for older adults with multimorbidity depend on conditions, medications, and geriatric risks that users may omit. We introduce ATLAS, a coupled graph--policy distillation framework for patient-adaptive medication safety. ATLAS structures guideline evidence as a medication-safety graph. Targeted questions update the patient state and distill relevant relations into a patient-specific medication conflict graph (PMCG). A risk-first multi-agent policy uses the PMCG to screen contraindications, assess cautions and monitoring needs, identify safer alternatives, and verify the final medication plan. We also introduce GeriMedBench, an interactive benchmark that tests safety-critical information acquisition and evidence-based decision revision. Across a European non-interactive multimorbidity benchmark, an Asian interactive multimorbidity benchmark, and an Asian non-interactive cross-guideline benchmark, ATLAS achieves the strongest complete-decision performance among the compared systems. On the European non-interactive multimorbidity benchmark, it exceeds the strongest proprietary LLM baseline by 53.73 points in Strict Success Rate and 14.63 points in overall safety reasoning score (OSRS), with no unsafe recommendations under the automated evaluator. A blinded clinician evaluation gives ATLAS higher mean ratings across all five criteria and flags potentially unsafe recommendations in one ATLAS case and two Gemini cases.
